Skip to main content
SpringerLink
Log in

Development of Multidrug-Resistance Convertors: Sense or Nonsense?

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

This review describes the clinical relevance of the two drugtransporters P-glycoprotein (Pgp) and multidrugresistance-associated protein (MRP) and the in vitrophenomenon which is referred to as multidrug resistance (MDR).The attempts to try to block these resistance mechanisms aresummarized with specific attention for the intentionallydesigned ``second generation'' MDR-convertors. Potentialexplanations of the limited clinical success rate are given andrecommendations for the design of future studies provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152–162, 1976

    Google Scholar 

  2. Sharom, FJ: The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160: 161–175, 1997

    Google Scholar 

  3. Gottesman, MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427, 1993

    Google Scholar 

  4. Twentyman PR: Transport proteins in drug resistance: biology and approaches to circumvention. J Intern Med 242: 133–137, 1997

    Google Scholar 

  5. Germann UA: P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927–944, 1996

    Google Scholar 

  6. Higgins CF, Gottesman MM: Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18–21, 1992

    Google Scholar 

  7. Zhu BT: A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol Carcinog 25: 1–13, 1999

    Google Scholar 

  8. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277–1287, 1990

    Google Scholar 

  9. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85–94, 1991

    Google Scholar 

  10. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber J, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80: 2729–2734, 1992

    Google Scholar 

  11. Schinkel AH, Smit JJ, van Teffingen 0, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491–502, 1994

    Google Scholar 

  12. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JMJM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028–4033, 1997

    Google Scholar 

  13. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJM, Borst P: Multidrug resistance and the role of Pglycoprotein knockout mice. Eur J Cancer 31 A: 1295–1298, 1995

    Google Scholar 

  14. Lankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxic Appl Pharmacol 143: 357–365, 1997

    Google Scholar 

  15. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science 258: 1650–1654, 1992

    Google Scholar 

  16. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902–5910, 1994

    Google Scholar 

  17. Vanhoefer U, Cao S, Harstrick A, Seeber S, Rusturn YM: Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 8: 1221–1228, 1997

    Google Scholar 

  18. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833–4836, 1994

    Google Scholar 

  19. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucoronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988–994, 1996

    Google Scholar 

  20. Barnouin K, Leier I, Jedlitschky G, Pourtier-Manzanedo A, König J, Lehmann WD, Keppler D: Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer 77: 201–209, 1998

    Google Scholar 

  21. Priebe W, Krawczyk M, Tien Kuo M, Yamane Y, Savaraj N, Ishikawa T: Doxorubicin-and daunorubicin-glutathione conjugates, but not unconjugated drugs, compelitively inhibit leukotrione C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 247: 859–863, 1998

    Google Scholar 

  22. Zaman GJ, Lankelma J, van Tellingen 0, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst: Role of glutathione in the export of compounds from protein. Prot Natl Acid Sci USA 92: 7690–7694, 1995

    Google Scholar 

  23. Loe DW, Deeley RG, Cole SPC: Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP). Evidence for cotransport with reduced glutathione. Cancer Res 58: 5130–5136, 1998

    Google Scholar 

  24. Ishikawa T, Bao JJ, Yamana Y, Akimaru K, Frindrich K, Wright CD, Kuo MT: Coordinated induction of MRP/GSX pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981–14988, 1996

    Google Scholar 

  25. Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, Jansen PLM, Muller M: Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112: 511–521, 1997

    Google Scholar 

  26. Evers R, Zaman GJR, van Deemster L, Jansen H, Calafat J, Oomen LCJM, Oude Elferink RPJ, Borst P, Schinkel AH: Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97: 1211–1218, 1996

    Google Scholar 

  27. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper FJ, Borst P: Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 188 (5): 397–808, 1998

    Google Scholar 

  28. Nooter K, Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768–780, 1996

    Google Scholar 

  29. Loe DW, Deeley RG, Cole SPC: Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A: 945–957, 1996

    Google Scholar 

  30. Deeley RG, Cole SPC: Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8: 193–204, 1997

    Google Scholar 

  31. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3: 1275–1279, 1997

    Google Scholar 

  32. Rappa G, Lorico A, Flavelli RA, Sartorelli AC: Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res 57: 5232–5237, 1997

    Google Scholar 

  33. Nooter K, Herweijer H: Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663–669, 1991

    Google Scholar 

  34. Hotta T. Tanimura H, Tsunoda T, lwahashi M, Tani M, Noguchi K, Mizobata S, Arii K, Terasawa H, Nakamori M, Yamaue H: P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells. Hepatogastroenterology 46: 316–321, 1999

    Google Scholar 

  35. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231–1237, 1996

    Google Scholar 

  36. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto H: Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355–1359, 1994

    Google Scholar 

  37. Kavallaris M, Leary JA, Barrett JA, Friedlander ML: MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 102: 7–16, 1996

    Google Scholar 

  38. Chan HS, Haddad G, Thomer PS, DeBoer G, Lin YR Ondrusek N, Yeger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608–1614, 1991

    Google Scholar 

  39. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SPC, Koike K, Kuwano M, Hori S: Expression of multidrug resistance protein gene in patients with gborna after chemotherapy. J Neuro-Oncol 40: 11–18, 1998

    Google Scholar 

  40. Stein U, Walther W, Wunderlich V: Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 10: 1541–1545, 1994

    Google Scholar 

  41. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowske A, Roessner A: Expression of multidrugresistance protein gene in human soft-tissue sarcomas. J Cancer Res Clin Oncol 122: 161–165, 1996

    Google Scholar 

  42. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Wahrer DC, Ossenkoppele GJ, Schuurhuis GJ: Theoretical and practical considerations for the measurement of P217 glycoprotein function in acute myeloid leukemia. Leukemia 11: 1110–1118, 1997

    Google Scholar 

  43. Webb M, Brun M, McNiven M, Le Couteur D, Craft P: MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 102: 710–717, 1998

    Google Scholar 

  44. Hokmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486–1491, 1992

    Google Scholar 

  45. Willman CL: The prognostic significance of the expression and function of multidrug-resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34: 25–33, 1997

    Google Scholar 

  46. Leith C, Kopecky K, Godwin J, McConnell T, Slovak ML, Chen l-M, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukernia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323–3329, 1997

    Google Scholar 

  47. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS: Relationship of the expression of the multidrug resistance gene product (Pglycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720–2726, 1991

    Google Scholar 

  48. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphocytic leukemia cells at diagnosis. Blood 79: 473–476, 1992

    Google Scholar 

  49. Goasguen JE, Dossot J-M, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81: 2394–2398, 1993

    Google Scholar 

  50. Zochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R: P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8: 974–977, 1994

    Google Scholar 

  51. Guerci A, Merlin JL, Missourn N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and p-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147–2153, 1995

    Google Scholar 

  52. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380–1385, 1995

    Google Scholar 

  53. Chin K-V, Kazumitsu U, Pastan 1, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459–462, 1992

    Google Scholar 

  54. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236: 1120–1122, 1987

    Google Scholar 

  55. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E: N-glycosylation and deletion mutants of the human mdr1 Pglycoprotein. J Biol Chem 268: 7474–7481, 1993

    Google Scholar 

  56. Nooter K, Westerman AM, Flens MJ, Zaman, GJR, Scheper, RJ, Van Wingerden KE, Burger, H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT, Stoter G: Expression of the multidrug resistanceassociated (MRP) gene in human cancers. Clin Cancer Res 1: 1301–1310, 1995

    Google Scholar 

  57. Filipits M, Suchomel RW, Dekan G, Stigibauer W, Haider K, Depisch D, Pirker R: Expression of the multidrug resistanceassociated protein (MRP) gene in colorectal carcinomas. Br J Cancer 75: 208–212, 1997

    Google Scholar 

  58. Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486–493, 1997

    Google Scholar 

  59. Nooter K, Brutel de la Riviere G, Klijn J, Stoter G, Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet 349: 1885–1886, 1997

    Google Scholar 

  60. Nooter K, Kok, T, Bosman FT, van Wingerden KE, Stoter G: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur J Cancer 34: 81–86, 1998

    Google Scholar 

  61. Takebayashi Y, Akiyama S, Natsugoe S, Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T, Aikou T: The expression of muffidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82: 661–666, 1998

    Google Scholar 

  62. Ota E, Abe Y, Oshika Y, Ozeki Y, lwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N, Nakamura M: Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72: 550–554, 1995

    Google Scholar 

  63. Narasaki F, Matsuo I, Ikuno N, Fukuda M, Soda H, Oka M: Multidrug resistanceassociated protein (MRP) gene expression in human lung cancer. Anticancer Res 16: 2079–2082, 1996

    Google Scholar 

  64. Nooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, Oostrum RG, Boersma AWM, van der Gaast A, Stoter G. Expression of the multidrug resistanceassociated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 7: 75–81, 1996

    Google Scholar 

  65. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH: Expression of the MRP and MDR1 multidrug resistance gene in small cell lung cancer. Clin Cancer Res 3: 115–122, 1997

    Google Scholar 

  66. Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M: Possible role of the multidrug resistanceassociated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 71: 108–115, 1997

    Google Scholar 

  67. Burger H, Nooter K, Zaman G.I. Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8: 990–997, 1994

    Google Scholar 

  68. Burger H, Nooter K, Sonneveld P, van Wingerden KE, Zaman GJ, Stoter G: High expression of the multidrug resistanceassociated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 88: 348–356, 1994

    Google Scholar 

  69. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M: Expression of the gene for multidrug-resistanceassociated protein and outcome in patients with neuroblastoma. N Engl J Med 334: 231–238, 1996

    Google Scholar 

  70. Nooter K, Oostrum R, Jonker R, van Dekken H, Stoikdijk W, van den Engh G: Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemother Pharmacol 23: 296–300, 1989

    Google Scholar 

  71. Twentyman PR: MDR1 (P-glycoprotein) gene expression-Implications for resistance modifiers trials. J Natl Cancer Inst 84: 1458–1460, 1992

    Google Scholar 

  72. Fine RL: Multidrug resistance. Cancer Chemother Biol Response Modif 10: 73–84, 1989

    Google Scholar 

  73. Tsuruo T, lida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukernia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972, 1981

    Google Scholar 

  74. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199, 1990

    Google Scholar 

  75. Bradshaw DM, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16 (11): 3674–3690, 1998

    Google Scholar 

  76. Advani R, Saba H, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukernia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93: 787–795, 1999

    Google Scholar 

  77. Planting AST, van der Gaast A, Sparreboom A, van der Burg MEL, de Boer M, Wissel PS, Jewell RC, Paul EM, Verweij J: Phase I and pharmacokinetic (PK) study targeting a 100 ng/mL plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (dox) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 199a, 1998 (abstract)

    Google Scholar 

  78. Ferry D, Moore M, Bartlett NL, Fyfe D, Oza A, Fracasso PM, Kersey K, Wissel PS, Jewell RC, Paul EM. Phase I and pharmacokinetic study targeting a 500 ng/ml plasma concentration of the potent multidrug resistance modulator GF120918 with doxorubicin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 922, 1998 (abstract)

    Google Scholar 

  79. Rowinsky EK, Smith L, Wang Y-M, Chaturvedi P, Vilialona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson Jr J, Harding MW, Von Hoff DD: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16: 2964–2976, 1998

    Google Scholar 

  80. Peck RA, Marshall J, Ziessman H, Hewett J, Schmalbach T, Chatuvedi P, Hawkins M: A phase I trial of doxorubicin and VX-710. Proc Am Assoc Cancer Res 37: 165, 1996 (abstract)

    Google Scholar 

  81. van Zuylen L, Sparreboom A, van der Gaast A, van der Berg MEL, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J: The orally administered P-glycoprotein inhibitor R101933 does not alter the pharmacokinetics of docetaxel results of a phase I study. Clin Cancer Res 6: 1365–1371, 2000

    Google Scholar 

  82. Awada A, Bleiberg H, Gil T, Di Leo A, Geurs F, de Valeriola D, McCabe S, Palmer PA, Woestenborghs R, Bol CJJG, Piccart MJ: Oral R101933, an inhibitor ofMDR1 P-glycoprotein does not significantly alter the pharmacokinetics and pharmacodynamics of paclitaxel. Proc Am Ass Cancer Res 40: 4373, 1999 (abstract)

    Google Scholar 

  83. Naito M, Tsuruo T: New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol 40: S20-S24, 1997

    Google Scholar 

  84. Naito S, Koike K, Ono M, Machida T, Tasaka S, Kiue A, Koga H, Kumazawa J: Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1-and MRPmediated multidrug resistance. Oncol Res 10: 123–132, 1998

    Google Scholar 

  85. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt W, Baughman TM, Bumol TF, Starling JJ: Reversal of Pglycoprotein-mediated multidrug resistance by a potent cyclopropyidibenzosuberane modulator, LY335979. Cancer Res 56: 4171–4179, 1996

    Google Scholar 

  86. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595–600, 1999

    Google Scholar 

  87. Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Chariton P, Templeton D, Bevan PB: In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer 79: 1672–1678, 1999

    Google Scholar 

  88. Beck JF, Buchholz F, Ulrich W-R, Boer R, Sanders KH, Niethammer D, Gekeler V: Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309–068, a newly designed pyridine derivative. Cancer Lett 129: 157–163, 1998

    Google Scholar 

  89. Chen H, Bamberger U, Heckel A, Guo X, Cheng Y: BIBW-22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 53: 1974–1977, 1993

    Google Scholar 

  90. List AF, Chakos H, Glinsmann-Gibson B, Bamberger U: Reversal of classical and non-P-glycoprotein (PGP)-mediated multidrug resistance (MDR) by BIBW-22. Blood 86: 516a, 1995 (abstract)

    Google Scholar 

  91. Gekeler V, Ise W, Sanders KH, Urich W, Beck J: The leukotreine LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208: 345–352, 1995

    Google Scholar 

  92. Vanhoefer U, Cao S, Minderman H, Tóth K, Scheper RJ, Slovak ML, Rusturn YM: PAK-104P, a pyridine analogue reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2: 369–377, 1996

    Google Scholar 

  93. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI: Decreased mutation rate for doxorubicin resistance and suppression of mdr1 gene activation by PSC 833. J Natl Cancer Inst 87: 1593–1602, 1995

    Google Scholar 

  94. Beck WT, Grogan TM, Wiliman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R: Methods to detect P-glycoproteinassociated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010–3020, 1996

    Google Scholar 

  95. Dalton WS, Grogan T, Salmon SE: Drug resistance in multiple myeloma. Cancer Res Ther Control 6: 189–190, 1998

    Google Scholar 

  96. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P: The human multidrug resistanceassociated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822–8826, 1994

    Google Scholar 

  97. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD: Expression of multidrug resistanceassociated protein in NIH/3T3 cells confers multidrug resistance associated with increased efflux and altered intracellular drug distribution. Cancer Res 55: 5342–5347, 1995

    Google Scholar 

  98. Versantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J, Broxterman HJ: Genistein modu219 lates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68: 939–946

  99. Versantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM: Competitive inhibiton by genistein and ATPdependence of daunorubicin transport in intact MRP overexpressing human small-cell lung cancer cells. Biochem Pharmacol 48: 1129–1136, 1994

    Google Scholar 

  100. Versantvoort CHM, Broxterman W, Bagrij T, Scheper RJ, Twentyman PR: Regulation of glutathione of drug transport in multidrug resitant human lung tumour cell lines overexpressing MRP. Br J Cancer 72: 82–89, 1995

    Google Scholar 

  101. Zaman GJR, Lankelma J, van Tellingen O, Beijen J, Dekker H, Paulusma C, Oude Sferink RPJ, Baas F, Borst P: Role of glutathione in the export of compounds from cells by the multidrug-resitance-associated protein. Proc Natl Acad Sci USA 92: 7690–7694, 1995

    Google Scholar 

  102. Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res 51: 67–72, 1991

    Google Scholar 

  103. Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE: Contribution of glutathione and glutathione-dependent enzymes in the reversal of Adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49: 688–695, 1991

    Google Scholar 

  104. Ma L, Krishnarnachary N, Center MS: Phosporylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338–3343,1995

    Google Scholar 

  105. Bertram J, Paifner K, Killian M, Brysch W, Schlingensiepen K-H, Hiddemann W, Kneba M: Reversal of multiple drug resistance in vitro by phosphorothioate olignucleotides and ribozymes. Anticancer Drugs 6: 124–134, 1995

    Google Scholar 

  106. Stewart AJ, Canitrot Y, Baracchini E, Dean NK Deeley RG, Cole SPC: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate olignucleotides. Biochem Pharmacol 51: 461–469, 1996

    Google Scholar 

  107. Rubin SC, Finstad CL, Hoskins WJ, Saigo PF, Provencher DM, Federici MG, Hakes TB, Markman M, Reichman BS, Lloyd KO, Lewis JL: Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 163: 69–73, 1990

    Google Scholar 

  108. Lehnert M, de Giuli R, Kunke K, Emerson S, Dalton WS, Salmon SE: Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur J Cancer 32A: 862–867, 1996

    Google Scholar 

  109. Smith AJ, Mayer U, Schinkel AH, Borst P: Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 90: 1161–1166, 1998

    Google Scholar 

  110. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58: 3248–3253, 1998

    Google Scholar 

  111. Tunggal X, Ballinger JR, Tannock IF: Influence of cell concentration in limiting the therapeutic benefit of Pglycoprotein reversal agent. Int J Cancer 81: 741–747, 1999

    Google Scholar 

  112. Relling MV: Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18: 350–356, 1996

    Google Scholar 

  113. Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L: PSC833: initial results in refractory ovarian cancer patients. Curr Opin Oncol 10: S21, 1998

    Google Scholar 

  114. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, and Löwenberg: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. Leukemia 10: 1741–1750, 1996

    Google Scholar 

  115. Boote DJ, Dennis IF, Twentyrnan PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610–618, 1996

    Google Scholar 

  116. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukernia. J Clin Oncol 15: 1796–1802, 1997

    Google Scholar 

  117. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJF, Eeltink C, Vermorken JB, Pinedo HM: A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3: 2005–2015, 1997

    Google Scholar 

  118. List AF, Spier C, Greer J, WoIff S, Hutter J, Dorr R, Salmon SE, Futcher B, Baier M, Dalton W: Phase I/II trial of cyclosporin as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11: 1652–1660, 1993

    Google Scholar 

  119. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI: Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 12: 835–842, 1994

    Google Scholar 

  120. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI: A phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 10: 1624–1634, 1992

    Google Scholar 

  121. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, De Angelis C, Bunting P: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837–4842, 1993

    Google Scholar 

  122. Pinedo HM, Giaccone G: P-glycoprotein-a marker of cancer-cell behavior. N Engl J Med 333: 1417–1419, 1995 (editorial)

    Google Scholar 

  123. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537–3547, 1997

    Google Scholar 

  124. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424, 1989

    Google Scholar 

  125. Dalton WS, Crowley JJ, Salmon S, Grogan TM, Laufman LR, Weiss G, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patient with refractory myeloma: A Southwest Oncology Group Study. Cancer 75: 815–820, 1995

    Google Scholar 

  126. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–259, 1992

    Google Scholar 

  127. Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM: Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group pilot Study. Cancer 85: 358–367, 1999

    Google Scholar 

  128. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn J-Y, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Ifrah N, Lamy Y, Audhuy B, Colombat P, Harousseau J-L: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88: 1198–1205, 1996

    Google Scholar 

  129. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphorna and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17–24, 1991

    Google Scholar 

  130. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995–2004, 1995

    Google Scholar 

  131. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE: A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs 9: 135–140, 1998

    Google Scholar 

  132. Milroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 68: 813–818, 1993

    Google Scholar 

  133. Ross HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM: Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer 18: 189–198, 1997

    Google Scholar 

  134. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MR, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaughnessy JA: Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14: 1173–1184, 1996

    Google Scholar 

  135. Wishart G, Bisset D, Paul J, Harnett JA, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB: Quinidine as a resitance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771–1777, 1994

    Google Scholar 

  136. Warner E, Heffley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R: Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4: 1451–1457, 1998

    Google Scholar 

  137. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting ASTh, Seynaeve C, Stoter G, Nooter K: A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64: 361–364, 1991

    Google Scholar 

  138. Rodenburg CJ, Nooter K, Herweijer H, Seynaeve, Oosterom R, Stoter G, Verweij J: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2: 305–306, 1991

    Google Scholar 

  139. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430–2436,1997

    Google Scholar 

  140. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454–1457, 1999

    Google Scholar 

  141. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acrid inecarboxam ide derivative. Cancer Res 53: 4595–4602, 1993

    Google Scholar 

  142. Sparreboom A, Planting AST, Jewell RC, de Bruijn P, Loos WJ, Paul EM, Wissel PS, Nooter K, Stoter G, Verweij J: Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti Cancer Drugs, in press

  143. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multi-drug resistant P-glycoprotein with an organtechnetium complex. Cancer Res 53: 977–984, 1993

    Google Scholar 

  144. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfil C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M: Fractional retention of Technetium-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38: 1348–1351, 1997

    Google Scholar 

  145. Chen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, Bates SE: Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m Sestamibi. Clin Cancer Res 3: 545–552, 1997

    Google Scholar 

  146. Hendriks NH, Franssen EJF, van der Graaf WTA, Meijer C, Piers DA, Vaalburg W, de Vries EGE: 99m-Tc-sestamibi is a substrate for P-glycoprotein and the multidrug resistanceassociated protein. Br J Cancer 77: 353–358, 1998

    Google Scholar 

  147. Whitherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS: Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7–12, 1996

    Google Scholar 

  148. Robey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T, Bates S: Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoproteinmediated drug efflux by PSC 833. Blood 93: 306–314

  149. Ruetz S, Brault M, Dalton W, Gros P: Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. Biochemistry 36: 8180–8188, 1997

    Google Scholar 

  150. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxel. J Natl Cancer Inst 83: 288–291, 1991

    Google Scholar 

  151. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517–2524, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, the Netherlands

    Lia van Zuylen, Kees Nooter, Alex Sparreboom & Jaap Verweij

Authors
  1. Lia van Zuylen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kees Nooter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alex Sparreboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaap Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Zuylen, L., Nooter, K., Sparreboom, A. et al. Development of Multidrug-Resistance Convertors: Sense or Nonsense?. Invest New Drugs 18, 205–220 (2000). https://doi.org/10.1023/A:1006487003814

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006487003814

Search

Navigation